| Molecular Formula | C11H7F6N3 |
| Molar Mass | 295.18 |
| Density | 1.52±0.1 g/cm3(Predicted) |
| Melting Point | 140-142 °C |
| Boling Point | 298.4±40.0 °C(Predicted) |
| pKa | 2.65±0.10(Predicted) |
| Storage Condition | under inert gas (nitrogen or Argon) at 2–8 °C |
| 1mg | 5mg | 10mg | |
|---|---|---|---|
| 1 mM | 3.388 ml | 16.939 ml | 33.877 ml |
| 5 mM | 0.678 ml | 3.388 ml | 6.775 ml |
| 10 mM | 0.339 ml | 1.694 ml | 3.388 ml |
| 5 mM | 0.068 ml | 0.339 ml | 0.678 ml |
| biological activity | CRAC intermediate 2 is an intermediate extracted from patent WO 2013059666A1 for the synthesis of CRAC series inhibitors. |